

RECEIVED
CENTRAL FAX CENTER

Docket No. 27693-01201

OCT 19 2004 U.S. Patent Application No. 09/436,347

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Christine A. WHITE et al.	Examiner: Alana M. Harris
Serial No. 09/436,347	Docket No.: 27693-01201
Filed: November 9, 1999	Group Art Unit: 1642
For: TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODY	

Hon. Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop Patent Application
Crystal City Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Listed on the accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

Docket No. 27693-01201


U.S. Patent Application No. 09/436,347

1. ☒ The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- a) ☒ We hereby authorize the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p) to be charged to Sidley Austin Brown & Wood LLP's Deposit Account No. 18-1260.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the document has been considered.

If Applicant has overlooked the payment of any fees with regard to the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 18-1260.

Respectfully submitted,



Jeffrey P. Kushan
Reg. No. 43,401
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, DC 20005
202-736-8000

Dated: October 19, 2004
JPK/SEP/yea
Enclosures

DCI 731806v1

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1201	Application No. 09/436,347
	Applicant(s): Christine A. WHITE et al.	Examiner: Alana M. Harris
	Filing Date: November 9, 1999	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		5,736,137	04/07/1998	Anderson , et al.			
		5,776,456	07/07/1998	Anderson , et al.			
		5,843,439	12/01/1998	Anderson , et al.			
		6,399,061	06/04/2002	Anderson , et al.			
		6,682,734	01/27/2004	Anderson , et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	McLaughlin, P. et al. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program." Journal of Clinical Oncology, Vol. 16, No. 8. August 1998, pp. 2825-2833.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 1